These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma. Wu L; Yun Z; Tagawa T; De la Maza L; Wu MO; Yu J; Zhao Y; de Perrot M Cancer Immunol Immunother; 2014 Dec; 63(12):1285-96. PubMed ID: 25183171 [TBL] [Abstract][Full Text] [Related]
24. A locus on mouse chromosome 13 inversely regulates CD1d expression and the development of invariant natural killer T-cells. Tsaih SW; Presa M; Khaja S; Ciecko AE; Serreze DV; Chen YG Genes Immun; 2015; 16(3):221-30. PubMed ID: 25654212 [TBL] [Abstract][Full Text] [Related]
25. Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice. VanderLaan PA; Reardon CA; Cabana VG; Wang CR; Getz GS Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540125 [TBL] [Abstract][Full Text] [Related]
26. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315 [TBL] [Abstract][Full Text] [Related]
27. Control of NKT cell differentiation by tissue-specific microenvironments. Yang Y; Ueno A; Bao M; Wang Z; Im JS; Porcelli S; Yoon JW J Immunol; 2003 Dec; 171(11):5913-20. PubMed ID: 14634102 [TBL] [Abstract][Full Text] [Related]
28. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. Bharhani MS; Chiu B; Na KS; Inman RD Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915 [TBL] [Abstract][Full Text] [Related]
29. All-trans-retinoic acid and CD38 ligation differentially regulate CD1d expression and α-galactosylceramide-induced immune responses. Chen Q; Ross AC Immunobiology; 2015 Jan; 220(1):32-41. PubMed ID: 25248321 [TBL] [Abstract][Full Text] [Related]
31. Activation of Invariant Natural Killer T Cells Redirects the Inflammatory Response in Neonatal Sepsis. Bolognese AC; Yang WL; Hansen LW; Sharma A; Nicastro JM; Coppa GF; Wang P Front Immunol; 2018; 9():833. PubMed ID: 29720984 [TBL] [Abstract][Full Text] [Related]
32. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Wu L; Parekh VV; Gabriel CL; Bracy DP; Marks-Shulman PA; Tamboli RA; Kim S; Mendez-Fernandez YV; Besra GS; Lomenick JP; Williams B; Wasserman DH; Van Kaer L Proc Natl Acad Sci U S A; 2012 May; 109(19):E1143-52. PubMed ID: 22493234 [TBL] [Abstract][Full Text] [Related]
33. JNK2 modulates the CD1d-dependent and -independent activation of iNKT cells. Liu J; Gallo RM; Khan MA; Iyer AK; Kratzke IM; Brutkiewicz RR Eur J Immunol; 2019 Feb; 49(2):255-265. PubMed ID: 30467836 [TBL] [Abstract][Full Text] [Related]
34. Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response. Lee YJ; Wang H; Starrett GJ; Phuong V; Jameson SC; Hogquist KA Immunity; 2015 Sep; 43(3):566-78. PubMed ID: 26362265 [TBL] [Abstract][Full Text] [Related]
35. A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model. Wen X; Kim S; Xiong R; Li M; Lawrenczyk A; Huang X; Chen SY; Rao P; Besra GS; Dellabona P; Casorati G; Porcelli SA; Akbari O; Exley MA; Yuan W J Immunol; 2015 Aug; 195(4):1459-69. PubMed ID: 26157173 [TBL] [Abstract][Full Text] [Related]
36. DOCK2 is required in T cell precursors for development of Valpha14 NK T cells. Kunisaki Y; Tanaka Y; Sanui T; Inayoshi A; Noda M; Nakayama T; Harada M; Taniguchi M; Sasazuki T; Fukui Y J Immunol; 2006 Apr; 176(8):4640-5. PubMed ID: 16585555 [TBL] [Abstract][Full Text] [Related]
37. Activation of Invariant Natural Killer T Cell Subsets in C57BL/6J Mice by Different Injection Modes of α-galactosylceramide. Meng M; Chen S; Gao X; Liu H; Zhao H; Zhang J; Zhang J; Chen D Iran J Allergy Asthma Immunol; 2020 Feb; 19(1):35-44. PubMed ID: 32245319 [TBL] [Abstract][Full Text] [Related]
38. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines. Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678 [TBL] [Abstract][Full Text] [Related]